Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPN-100 (Ravicti) Long-Term Safety in Urea Cycle Disorders
NCT00947297Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2009
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of sodium phenylbutyrate in urea cycle disorders (UCD), sponsored by Amgen. Started Nov 2009; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
urea cycle disorders (UCD)
Beyond the preview
Go deeper on NCT00947297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00947297.